novo nordisk glp-1 receptor agonist RA education GLP-1 Receptor Agonist Market Growth
Description
Stay at the current dose until GI symptoms have resolved for at least two full weeks
In follow-up from the STEP 1 trial on semaglutide, average weight loss on semaglutide was 17.3% at week 68
Certain conditions may preclude Ozempic use, and our experienced healthcare providers will assess each patient before prescribing it
This allows your provider to advocate directly for your treatment
Recent Developments In February 2026 , Pfizer announced positive Phase 2b trial results for its ultra-long-acting injectable GLP-1 (PF-08653944), demonstrating significant weight loss with monthly dosing
Scientific studies have demonstrated its remarkable effectiveness, with an average reduction in body weight of 15 to 20 percent observed in patients
